Genentech, Inc. Granted Patent for TDO2 Inhibitors
Summary
The USPTO has granted Genentech, Inc. patent US12583858B2 for TDO2 inhibitors. These inhibitors are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing anti-cancer treatments. The patent was filed on October 12, 2020.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12583858B2 to Genentech, Inc. This patent covers inhibitors of cellularly expressed TD02, which are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing the effectiveness of anti-cancer treatments. The patent application was filed on October 12, 2020, and the grant is effective March 24, 2026.
This patent grant signifies a new intellectual property right for Genentech, Inc. regarding their TDO2 inhibitor technology. While not imposing direct compliance obligations on other entities, it establishes exclusive rights that may impact future research, development, and commercialization efforts in this therapeutic area. Companies operating in the oncology and immunology space should be aware of this patent's scope to avoid potential infringement.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TDO2 inhibitors
Grant US12583858B2 Kind: B2 Mar 24, 2026
Assignee
Genentech, Inc.
Inventors
Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers
Abstract
Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
CPC Classifications
C07D 487/04 C07D 519/00 A61K 38/16 A61K 45/06 A61K 2300/00 A61P 35/00 A61P 35/02
Filing Date
2020-10-12
Application No.
17068574
Claims
14
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.